Karyopharm Therapeutics (KPTI) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Karyopharm Therapeutics (NASDAQ: KPTI) recently:

  • 4/10/2018 – Karyopharm Therapeutics had its price target raised by analysts at JPMorgan Chase from $19.00 to $20.00. They now have an “overweight” rating on the stock.
  • 4/10/2018 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $22.00 price target on the stock. They wrote, “We had the pleasure of hosting Karyopharm CEO Michael Kauffman and CFO Mike Falvey for meetings with institutional investors in New York City. Overall, investors focused on upcoming and potentially registration-supporting datasets for lead drug candidate selinexor in two trials: STORM in penta-refractory multiple myeloma (April 30) and SADAL in relapsed/refractory diffuse large B-cell lymphoma (DLBCL, 2H). We came away with increased confidence that Accelerated Approval is a viable path for selinexor, continue to view the available data as indicative of benefit, and reiterate our BUY rating and $22 PT.””
  • 4/3/2018 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 4/2/2018 – Karyopharm Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $19.00 price target on the stock.
  • 3/21/2018 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
  • 3/21/2018 – Karyopharm Therapeutics was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “STORM Data. Top-line data from the STORM (Phase IIb) trial in penta- refractory multiple myeloma, which has been granted accelerated approval, are expected in late-April.””
  • 3/20/2018 – Karyopharm Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 3/16/2018 – Karyopharm Therapeutics had its “overweight” rating reaffirmed by analysts at JPMorgan Chase. They now have a $19.00 price target on the stock, up previously from $18.00.
  • 3/15/2018 – Karyopharm Therapeutics was given a new $22.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 3/15/2018 – Karyopharm Therapeutics had its price target raised by analysts at HC Wainwright to $26.00. They now have a “buy” rating on the stock.
  • 3/15/2018 – Karyopharm Therapeutics was given a new $18.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 3/12/2018 – Karyopharm Therapeutics had its price target raised by analysts at Canaccord Genuity from $18.00 to $22.00. They now have a “buy” rating on the stock.
  • 3/8/2018 – Karyopharm Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 3/2/2018 – Karyopharm Therapeutics had its “buy” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $22.00 price target on the stock.

KPTI traded up $0.15 during trading on Monday, hitting $14.05. The company’s stock had a trading volume of 456,292 shares, compared to its average volume of 392,922. Karyopharm Therapeutics has a twelve month low of $7.48 and a twelve month high of $18.00. The firm has a market cap of $690.17, a P/E ratio of -5.00 and a beta of 3.61.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The business had revenue of $1.53 million during the quarter, compared to the consensus estimate of $2.26 million. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. The company’s revenue for the quarter was up 3163.8% compared to the same quarter last year. analysts anticipate that Karyopharm Therapeutics will post -2.82 earnings per share for the current fiscal year.

In other Karyopharm Therapeutics news, EVP Christopher Brett Primiano sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.01, for a total value of $37,525.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $10.09, for a total value of $100,900.00. Following the completion of the sale, the chief executive officer now directly owns 522,143 shares in the company, valued at $5,268,422.87. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,000 shares of company stock worth $952,625. 14.71% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $115,000. MetLife Investment Advisors LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $146,000. Two Sigma Investments LP boosted its stake in shares of Karyopharm Therapeutics by 76.8% in the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after acquiring an additional 10,520 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Karyopharm Therapeutics by 18.8% in the fourth quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after acquiring an additional 4,902 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $355,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply